A Study of LY3457263 in Obese Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT05582096
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • LY3457263 — DRUG
    Administered SC.
  • Tirzepatide — DRUG
    Administered SC.
  • Placebo — DRUG
    Administered SC.

Study Details

The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.

Key Dates

Start date
Nov 11, 2022
Status verified
Jul 2023
Primary completion
Jun 8, 2023
Completion
Jun 8, 2023

Study Design

Enrollment
38 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3457263 + Tirzepatide
    LY3457263 administered subcutaneously (SC) in combination with tirzepatide given SC.
  • Placebo Comparator: Placebo + Tirzepatide
    Placebo administered SC in combination with tirzepatide given SC.

Primary Outcome Measure

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to 11 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
LabCorp CRU, Inc.Daytona BeachFlorida32117-

Find similar trials in Daytona Beach, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
LabCorp CRU, Inc.· Daytona Beach, FL

Related Studies